Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Experimental Gerontology

Volumn 45, Issue 10, 2010, Pages 744-751

  Krautwald, Martina ^a   Münch, Gerald ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Advanced glycation end products; AGE lowering agents; Alzheimer's disease; Carbonyl stress; Gerontotoxins; Methylglyoxal

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMIFOSTINE; AMINOGUANIDINE; AMINOTHIOL; AMYLOID BETA PROTEIN; BENFOTIAMINE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; GENTAMICIN; GLUTATHIONE; GLYOXALASE; HYDRALAZINE; ISONIAZID; MERCAPTAMINE; METFORMIN; METHYLGLYOXAL; NEUROTOXIN; PENICILLAMINE; TENILSETAM; THIAMINE; THIAZOLE DERIVATIVE; THIAZOLIUM DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; BIOCHEMISTRY; CEREBROSPINAL FLUID; CROSS LINKING; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; AGING; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PYRUVALDEHYDE; RISK FACTORS;

EID: 77956989586     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2010.03.001     Document Type: Review

References (83)

1. Abordo E.A., Minhas H.S., Thornalley P.J. Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem. Pharmacol. 1999, 58:641-648.
2. Ahmed M.U., Thorpe S.R., Baynes J.W. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 1986, 261:4889-4894.
3. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., Münch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 2005, 92:255-263.
4. Anderson M.M., Requena J.R., Crowley J.R., Thorpe S.R., Heinecke J.W. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 1999, 104:103-113.
5. Bar K.J., Franke S., Wenda B., Muller S., Kientsch-Engel R., Stein G., Sauer H. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol. Aging 2003, 24:333-338.
6. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G., Smith M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 2001, 31:175-180.
7. Chen F., Wollmer M.A., Hoerndli F., Münch G., Kuhla B., Rogaev E.I., Tsolaki M., Papassotiropoulos A., Gotz J. Role for glyoxalase I in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2004, 101:7687-7692.
8. Chng H.T., New L.S., Neo A.H., Goh C.W., Browne E.R., Chan E.C. Distribution study of orally administered lipoic acid in rat brain tissues. Brain Res. 2009, 1251:80-86.
9. Colaco C.A., Ledesma M.D., Harrington C.R., Avila J. The role of the Maillard reaction in other pathologies: Alzheimer's disease. Nephrol. Dial. Transplant. 1996, (11 Suppl. 5):7-12.
10. Dukic-Stefanovic S., Schinzel R., Riederer P., Münch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?. Biogerontology 2001, 2:19-34.
11. Dunn J.A., Ahmed M.U., Murtiashaw M.H., Richardson J.M., Walla M.D., Thorpe S.R., Baynes J.W. Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990, 29:10964-10970.
12. Freixes M., Rodriguez A., Dalfo E., Ferrer I. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol. Aging 2006, 27:1807-1815.
13. Fuller S., Münch G., Steele M. Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert Rev. Neurother. 2009, 9:1585-1594.
14. Fuller, S., Steele, M., Münch, G., 2009b. Activated astroglia during chronic inflammation in Alzheimer's disease - do they neglect their neurosupportive roles? Mutat. Res. 2009 Sep 11 [Epub ahead of print].
15. Gasser A., Forbes J.M. Advanced glycation: implications in tissue damage and disease. Protein Pept. Lett. 2008, 15:385-391.
16. Girones X., Guimera A., Cruz-Sanchez C.Z., Ortega A., Sasaki N., Makita Z., Lafuente J.V., Kalaria R., Cruz-Sanchez F.F. N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic. Biol. Med. 2004, 36:1241-1247.
17. Glomb M.A., Monnier V.M. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 1995, 270:10017-10026.
18. Gotz J., Ittner L.M., Schonrock N. Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?. Med. J. Aust. 2006, 185:381-384.
19. Guix F.X., Ill-Raga G., Bravo R., Nakaya T., de Fabritiis G., Coma M., Miscione G.P., Villa-Freixa J., Suzuki T., Fernandez-Busquets X., Valverde M.A., de Strooper B., Munoz F.J. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Brain 2009, 132:1335-1345.
20. Hammes H.P. Pathophysiological mechanisms of diabetic angiopathy. J. Diabetes Complications 2003, 17:16-19.
21. Han D., Handelman G., Marcocci L., Sen C.K., Roy S., Kobuchi H., Tritschler H.J., Flohe L., Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 1997, 6:321-338.
22. Heidland A., Schinzel R., Sebekova K., Xiang G., Münch G., Simm A. Advanced glycation endproducts and the kidney. Przegl. Lek. 1998, (55 Suppl. 1):29-31.
23. Hilbig R., Rahmann H. Comparative autoradiographic investigations on the tissue distribution of benfotiamine versus thiamine in mice. Arzneimittelforschung 1998, 48:461-468.
24. Hipkiss A.R. Does chronic glycolysis accelerate aging? Could this explain how dietary restriction works?. Ann. NY Acad. Sci. 2006, 1067:361-368.
25. Horie K., Miyata T., Yasuda T., Takeda A., Yasuda Y., Maeda K., Sobue G., Kurokawa K. Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem. Biophys. Res. Commun. 1997, 236:327-332.
26. Hoyer S., Oesterreich K., Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?. J. Neurol. 1988, 235:143-148.
27. Hultberg M., Hultberg B. The effect of different antioxidants on glutathione turnover in human cell lines and their interaction with hydrogen peroxide. Chem. Biol. Interact. 2006, 163:192-198.
28. Issels R.D., Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res. 1989, 49:2082-2086.
29. Jono T., Kimura T., Takamatsu J., Nagai R., Miyazaki K., Yuzuriha T., Kitamura T., Horiuchi S. Accumulation of imidazolone, pentosidine and N(epsilon)-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. Pathol. Int. 2002, 52:563-571.
30. Khalifah R.G., Baynes J.W., Hudson B.G. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 1999, 257:251-258.
31. Kimura T., Takamatsu J., Araki N., Goto M., Kondo A., Miyakawa T., Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?. Neuroreport 1995, 6:866-868.
32. Kuhla B., Boeck K., Lüth H.J., Schmidt A., Weigle B., Schmitz M., Ogunlade V., Münch G., Arendt T. Age-dependent changes of glyoxalase I expression in human brain. Neurobiol. Aging 2006, 27:815-822.
33. Kuhla B., Boeck K., Schmidt A., Ogunlade V., Arendt T., Münch G., Lüth H.J. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol. Aging 2007, 28:29-41.
34. Kuhla B., Haase C., Flach K., Lüth H.J., Arendt T., Münch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J. Biol. Chem. 2007, 282:6984-6991.
35. Ledesma M.D., Bonay P., Colaco C., Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 1994, 269:21614-21619.
36. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., Palumbo P.J. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 1997, 145:301-308.
37. Lin M.T., Hoo S.L. Regional distribution of sodium acetylsalicylate in the brain of normothermic and hyperthermic rabbits. Can. J. Physiol. Pharmacol. 1980, 58:85-88.
38. Loske C., Gerdemann A., Schepl W., Wycislo M., Schinzel R., Palm D., Riederer P., Münch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 2000, 267:4171-4178.
39. Loske C., Neumann A., Cunningham A.M., Nichol K., Schinzel R., Riederer P., Münch G. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J. Neural Transm. 1998, 105:1005-1015.
40. Luchsinger J.A., Tang M.X., Stern Y., Shea S., Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 2001, 154:635-641.
41. Lüth H.J., Ogunlade V., Kuhla B., Kientsch-Engel R., Stahl P., Webster J., Arendt T., Münch G. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb. Cortex 2005, 15:211-220.
42. Malik N.S., Meek K.M. The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds. Biochem. Biophys. Res. Commun. 1994, 199:683-686.
43. McLellan L.I., Lewis A.D., Hall D.J., Ansell J.D., Wolf C.R. Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis 1995, 16:2099-2106.
44. Mehlhorn G., Hollborn M., Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 2000, 18:423-431.
45. Miyata S., Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J. Clin. Invest. 1992, 89:1102-1112.
46. Monnier V.M., Stevens V.J., Cerami A. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog. Food Nutr. Sci. 1981, 5:315-327.
47. Moreira P.I., Santos M.S., Oliveira C.R., Shenk J.C., Nunomura A., Smith M.A., Zhu X., Perry G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol. Disord. Drug Targets 2008, 7:3-10.
48. Münch G., Gerlach M., Sian J., Wong A., Riederer P. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress?. Ann. Neurol. 1998, 44:S85-S88.
49. Münch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., Vlassara H., Smith M.A., Perry G., Riederer P. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural Transm. 1998, 105:439-461.
50. Münch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Muller R., Neumann A., Schinzel R., Cunningham A.M. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta 1997, 1360:17-29.
51. Münch G., Thome J., Foley P., Schinzel R., Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Brain Res. Rev. 1997, 23:134-143.
52. Münch G., Schicktanz D., Behme A., Gerlach M., Riederer P., Palm D., Schinzel R. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat. Biotechnol. 1999, 17:1006-1010.
53. Münch G., Shepherd C.E., McCann H., Brooks W.S., Kwok J.B., Arendt T., Hallupp M., Schofield P.R., Martins R.N., Halliday G.M. Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. Neuroreport 2002, 13:601-604.
54. Münch G., Taneli Y., Schraven E., Schindler U., Schinzel R., Palm D., Riederer P. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J. Neural Transm. Park. Dis. Dement. Sect. 1994, 8:193-208.
55. Muntane G., Dalfo E., Martinez A., Rey M.J., Avila J., Perez M., Portero M., Pamplona R., Ayala V., Ferrer I. Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. J. Neurochem. 2006, 99:177-185.
56. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392-1397.
57. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
58. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 2002, 4:191-209.
59. Retz W., Gsell W., Münch G., Rosler M., Riederer P. Free radicals in Alzheimer's disease. J. Neural Transm. Suppl. 1998, 54:221-236.
60. Rindi G. Metabolism of thiamin and its phosphoric esters in different regions of the nervous system: a new approach. Acta Vitaminol. Enzymol. 1982, 4:59-68.
61. Robinson S.R., Bishop G.M., Münch G. Alzheimer vaccine: amyloid-beta on trial. Bioessays 2003, 25:283-288.
62. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 2006, 21:197-208.
63. Schinzel R., Münch G., Heidland A., Sebekova K. Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001, 87:295-303.
64. Schubert D. Glucose metabolism and Alzheimer's disease. Ageing Res. Rev. 2005, 4:240-257.
65. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 2001, 22:397-402.
66. Smith M.A., Sayre L.M., Vitek M.P., Monnier V.M., Perry G. Early AGEing and Alzheimer's. Nature 1995, 374:316.
67. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 1994, 91:5710-5714.
68. Spector R. The transport of gentamicin in the choroid plexus and cerebrospinal fluid. J. Pharmacol. Exp. Ther. 1975, 194:82-88.
69. Stuhlmiller D.F., Boje K.M. Characterization of l-arginine and aminoguanidine uptake into isolated rat choroid plexus: differences in uptake mechanisms and inhibition by nitric oxide synthase inhibitors. J. Neurochem. 1995, 65:68-74.
70. Swamy M.S., Abraham E.C. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 1989, 30:1120-1126.
71. Taguchi T., Sugiura M., Hamada Y., Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem. Pharmacol. 1998, 55:1667-1671.
72. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 2008, 14:973-978.
73. Tan A.L., Forbes J.M., Cooper M.E. AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 2007, 27:130-143.
74. Thornalley P.J., Jahan I., Ng R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J. Biochem. (Tokyo) 2001, 129:543-549.
75. Thorpe S.R., Baynes J.W. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996, 9:69-77.
76. Vecsei L., Kovacs G.L., Faludi M., Bollok I., Telegdy G. Dose-related effects of cysteamine treatment on hypothalamic and striatal dopamine, noradrenaline and serotonin neurotransmission. Acta Physiol. Hung. 1985, 66:213-217.
77. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91:4766-4770.
78. Webster J., Urban C., Berbaum K., Loske C., Alpar A., Gartner U., de Arriba S.G., Arendt T., Münch G. The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox. Res. 2005, 7:95-101.
79. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem. J. 1987, 245:243-250.
80. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., Huijberts M.S., Poitevin P., Swennen G.N., Vasan S., Egan J.J., Ulrich P., Cerami A., Levy B.I. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. USA 1998, 95:4630-4634.
81. Wondrak G.T., Cervantes-Laurean D., Roberts M.J., Qasem J.G., Kim M., Jacobson E.L., Jacobson M.K. Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress. Biochem. Pharmacol. 2002, 63:361-373.
82. Wong A., Lüth H.J., Deuther-Conrad W., Dukic-Stefanovic S., Gasic-Milenkovic J., Arendt T., Münch G. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res. 2001, 920:32-40.
83. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Koga K., Sasaki N., Yamamoto H., Takeuchi M., Makita Z. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun. 2002, 290:973-978.